Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated...

cafead

Administrator
Staff member
  • cafead   May 17, 2018 at 09:52: AM
via
  • Exelixis will receive a milestone payment of $50 million
  • Approval based on Cabometyx vs versus sunitinib in CABOSUN trial
  • Cabometyx was approved for reimbursement in most European countries by May of 2018

article source